NRx Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,576,911. This patent, issued to Glytech LLC, is exclusively licensed to NeuroRx, Inc., a wholly owned subsidiary of NRx, under the terms of a license agreement with Glytech through which NeuroRx has the sole rights to this and other patents, both U.S. and international.
Feb. 22, 2023NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions – Adds New U.S. Patent to Portfolio
Nov. 9, 2022NRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process
NRx Pharmaceuticals, Inc. today announced the release of the first batches manufactured in the U.S. of NRX-101, its Phase 3-ready investigational drug, targeting suicidal bipolar depression and with future study plans for post-traumatic stress disorder (PTSD).